119 related articles for article (PubMed ID: 28262346)
1. Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?
Frommeyer G; Sterneberg M; Dechering DG; Ellermann C; Bögeholz N; Kochhäuser S; Pott C; Fehr M; Eckardt L
Int J Cardiol; 2017 Jun; 236():237-243. PubMed ID: 28262346
[TBL] [Abstract][Full Text] [Related]
2. Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.
Frommeyer G; Sterneberg M; Dechering DG; Kaese S; Bögeholz N; Pott C; Fehr M; Bogossian H; Milberg P; Eckardt L
Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039911
[TBL] [Abstract][Full Text] [Related]
3. The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.
Frommeyer G; Mittelstedt A; Wolfes J; Ellermann C; Kochhäuser S; Leitz P; Dechering DG; Eckardt L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1155-1161. PubMed ID: 28780600
[TBL] [Abstract][Full Text] [Related]
4. Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure.
He Z; Sun C; Xu Y; Cheng D
Biomed Pharmacother; 2016 Dec; 84():1760-1767. PubMed ID: 27847200
[TBL] [Abstract][Full Text] [Related]
5. Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model.
Frommeyer G; Kohnke A; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Fehr M; Eckardt L
Int J Cardiol; 2017 Jun; 236():423-426. PubMed ID: 28132779
[TBL] [Abstract][Full Text] [Related]
6. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.
Frommeyer G; Schmidt M; Clauß C; Kaese S; Stypmann J; Pott C; Eckardt L; Milberg P
Eur J Heart Fail; 2012 Dec; 14(12):1322-31. PubMed ID: 23099358
[TBL] [Abstract][Full Text] [Related]
7. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vernakalant and ranolazine in atrial fibrillation.
Frommeyer G; Sterneberg M; Dechering DG; Kochhäuser S; Bögeholz N; Fehr M; Eckardt L
J Cardiovasc Med (Hagerstown); 2017 Sep; 18(9):663-668. PubMed ID: 28692548
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias.
Frommeyer G; Weller J; Ellermann C; Bögeholz N; Leitz P; Dechering DG; Kochhäuser S; Wasmer K; Eckardt L
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):526-530. PubMed ID: 28627809
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
[TBL] [Abstract][Full Text] [Related]
11. Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.
Uemura K; Inagaki M; Zheng C; Kawada T; Li M; Fukumitsu M; Sugimachi M
Heart Vessels; 2017 Apr; 32(4):484-494. PubMed ID: 27844147
[TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation.
Wolfes J; Ellermann C; Broer N; Rath B; Willy K; Leitz PR; Lange PS; Eckardt L; Frommeyer G
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33092020
[TBL] [Abstract][Full Text] [Related]
13. Action Potential Triangulation Explains Acute Proarrhythmic Effect of Aliskiren in a Whole-Heart Model of Atrial Fibrillation.
Ellermann C; Mittelstedt A; Wolfes J; Willy K; Leitz P; Reinke F; Eckardt L; Frommeyer G
Cardiovasc Toxicol; 2020 Feb; 20(1):49-57. PubMed ID: 31175534
[TBL] [Abstract][Full Text] [Related]
14. Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.
Frommeyer G; Weller J; Ellermann C; Kaese S; Kochhäuser S; Lange PS; Dechering DG; Eckardt L
Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):941-945. PubMed ID: 28556923
[TBL] [Abstract][Full Text] [Related]
15. Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Saengklub N; Limprasutr V; Sawangkoon S; Hamlin RL; Kijtawornrat A
Exp Anim; 2017 Aug; 66(3):251-258. PubMed ID: 28381818
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation.
Verrier RL; Sobrado MF; Pagotto VP; Kanas AF; Machado AD; Varone BB; Sobrado LF; Nearing BD; Zeng D; Belardinelli L
Heart Rhythm; 2013 Nov; 10(11):1692-7. PubMed ID: 23933296
[TBL] [Abstract][Full Text] [Related]
17. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
18. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.
Verrier RL; Silva AF; Bonatti R; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
J Cardiovasc Electrophysiol; 2015 Mar; 26(3):329-35. PubMed ID: 25346368
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.
Aidonidis I; Doulas K; Hatziefthimiou A; Tagarakis G; Simopoulos V; Rizos I; Tsilimingas N; Molyvdas PA
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):94-101. PubMed ID: 22872232
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine Prevents Levosimendan-Induced Atrial Fibrillation.
Ellermann C; Kohnke A; Dechering DG; Kochhäuser S; Reinke F; Fehr M; Eckardt L; Frommeyer G
Pharmacology; 2018; 102(3-4):138-141. PubMed ID: 29982246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
